| Ovarian Cancer |
1 |
1 |
| Biologic Therapy |
0 |
1 |
| Breast Cancer |
0 |
1 |
| Cancer |
0 |
0.74 |
| Gynecological cancers |
0 |
0.56 |
| Genomic Medicine |
0 |
0.52 |
| Toxicology |
0 |
0.49 |
| Angiogenesis Inhibitors |
0 |
0.48 |
| Humanized Monoclonal Antibody |
0 |
0.48 |
| Chemotherapy |
0 |
0.26 |
| BRCA |
0 |
0.22 |
| Immunotherapy |
0 |
0.13 |
| Surgery |
0 |
0.13 |
| Tumor |
0 |
0.13 |
| Genetic Testing |
0 |
0.09 |
| Genetics |
0 |
0.09 |
| Insurance |
0 |
0.09 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.08 |